ArticleFrontiers in medicine2026
Evaluating the value of lactic dehydrogenase in anti-MDA5-positive Dermatomyositis associated with interstitial lung disease.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective cohort study aimed to investigate the relationship between lactic dehydrogenase (LDH) and anti-melanoma differentiation-associated gene 5 antibodies-positive dermatomyositis (anti-MDA5-positive DM) associated with interstitial lung disease (ILD). Method: A total of 168 anti-MDA5-positive DM patients with ILD underwent comprehensive evaluation, including LDH, anti-Ro-52 antibodies, serum ferritin determination, and lung high-resolution computed tomography (CT). Results: The levels of LDH were significantly elevated in anti-MDA5-positive DM patients compared with the control group ( Conclusion: (1) The LDH levels were affected by anti-Ro-52 antibodies and serum ferritin. (2) The severity of ILD in anti-MDA5-positive DM patients was positively correlated with LDH, suggesting that LDH might serve as an effective assessment indicator to evaluate the changes in ILD in these patients. (3) Elevated LDH levels were a crucial indicator of poor prognosis in anti-MDA5-positive DM patients, warranting close attention from rheumatologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.